Epioni: Based on research from Dr. Stavroula Kousteni’s lab, Epioni is a virtual company developing a combination therapy that prevents the pathogenesis of a preleukemia, called Myelodysplastic Syndrome (MDS), to Acute Myeloid Leukemia (AML) and prognostic markers to predict clinical outcomes. Worldwide there are 87,000 new cases of MDS each year, with 33% of all MDS patients developing AML. Currently there are no therapies that prevent the progression of MDS to AML, and with current treatments complete AML remission is rare. The company uses combination therapy comprised of humanized Jagged1 antibody co-administered along with FDA-approved All-trans-retinoic acid (ATRA) that prolonged survival and prevent the onset of leukemia in a murine model. Twenty times the expected human therapeutic dose of the antibody was shown safe in rodents.